Cell-Free Bacteriophage Synthesis Through E. Coli Gene Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current phage therapy manufacturing processes face challenges such as low yields, logistical issues, and instability of bacteriophage preparations, which are exacerbated by the need for well-characterized hosts and purification methods that often result in significant loss of titer and shelf-stability problems.

Innovation Solution

Genetically modified E. coli host cells overexpressing translation initiation factor IF-3 (infC), OxyS, and/or CyaR, and/or utilizing CRISPR enzymes to target specific promoter regions, combined with cell lysates for enhanced cell-free bacteriophage synthesis (CFBS) to improve yields and stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional cell-free bacteriophage synthesis methods are used, then the process is simple, but the yield is low

Engineering Contradiction:

Improvebacteriophage yieldVSAvoidhost cell modification complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent modifies the genetic parameters of the host cell by overexpressing specific genes (infC, oxyS, cyaR) to change the transcriptional and translational activity parameters, thereby increasing bacteriophage yield in the cell-free synthesis system

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent divides the host cell genome into specific target segments (infC, oxyS, cyaR genes) and modifies only these segments through targeted overexpression, leaving the rest of the cell machinery unchanged to maintain simplicity

Inventive Principle:

Principle #1Segmentation

2Object-affected harmful factors

If crude phage preparations are purified using organic solvent extraction or affinity column methods, then endotoxin is removed, but significant loss of titer occurs

Engineering Contradiction:

Improveendotoxin removalVSAvoidphage titer loss

Core Design Contradiction:

Object-affected harmful factorsVSLoss of substance

Solution Approach 1:

The patent extracts and removes the RecBCD exonuclease enzyme (specifically the RecC subunit) from the host cell system, which is responsible for degrading phage DNA during purification, thereby preventing titer loss while maintaining endotoxin removal capabilities

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces an intermediary mechanism by using CRISPR-Cas system to specifically target and inhibit RecBCD exonuclease activity, mediating protection of phage DNA from degradation during the purification process

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If RecBCD exonuclease activity is present in the host cell, then DNA repair functions are maintained, but phage DNA is degraded reducing synthesis efficiency

Engineering Contradiction:

Improvebacteriophage synthesis efficiencyVSAvoidDNA repair function

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies local quality change by specifically inhibiting the RecBCD exonuclease activity only in the context of phage DNA processing, while potentially maintaining other DNA repair functions through selective targeting of the RecC subunit

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent converts the harmful DNA degradation activity of RecBCD exonuclease into a beneficial situation by using CRISPR-Cas to specifically inhibit this activity, thereby protecting phage DNA and improving synthesis efficiency while the host cell can still perform other essential functions

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified host cells and CRISPR-mediated approaches significantly enhance CFBS yields and stability, providing improved bacteriophage production efficiency and shelf-life, addressing the limitations of conventional methods.

Implementation Method 1

a vector that includes a nucleic acid sequence encoding a CRISPR enzyme and a vector that includes a nucleic acid sequence encoding a crRNA that specifically targets a promoter region located upstream of a transcription start site (TSS) of recC

Methodology Applied

Scientific EffectCRISPR-Cas system:

Implementation Method 2

genetically modified bacterial host cells (e.g., E. coli) that overexpress one or more of translation initiation factor IF-3 (infC)

Methodology Applied

Scientific EffectTranslation initiation:

Implementation Method 3

overexpress one or more of translation initiation factor IF-3 (infC), OxyS and CyaR

Methodology Applied

Scientific EffectTranscriptional regulation:

Data Source

PatentUS20250283053A1Enhanced cell-free bacteriophage synthesis by genetic modulation of bacterial transcription/translation machinery (TXTL) machinery

Publication Date: 2025.09.11 THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

AI summary

The present disclosure relates to compositions including or obtained from genetically modified bacterial host cells (e.g., E. coli) and methods for using the same for cell-free bacteriophage synthesis (CFBS). In particular, the present technology relates to genetically modified E. coli that overexpress one or more of translation initiation factor IF-3 (infC), OxyS and CyaR and/or repress RecC subunit exonuclease RecBCD, and methods for using the same to obtain improved CFBS yields.